U.S. patent application number 14/364228 was filed with the patent office on 2014-11-13 for modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin.
This patent application is currently assigned to Alize Pharma SAS. The applicant listed for this patent is Alize Pharma SAS. Invention is credited to Thierry Abribat, Aart Jan Van Der Lely.
Application Number | 20140336109 14/364228 |
Document ID | / |
Family ID | 47780096 |
Filed Date | 2014-11-13 |
United States Patent
Application |
20140336109 |
Kind Code |
A1 |
Van Der Lely; Aart Jan ; et
al. |
November 13, 2014 |
MODULATION OF GHRELIN LEVELS AND GHRELIN/UNACYLATED GHRELIN RATIO
USING UNACYLATED GHRELIN
Abstract
A method and a composition for decreasing ghrelin levels and/or
decreasing ghrelin/unacylated ghrelin ratio in a subject, the
method comprising administering an effective amount of unacylated
ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof to the subject wherein a
reduction in ghrelin levels and/or a reduction in
ghrelin/unacylated ghrelin ratio is beneficial to the subject.
Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio
as biomarkers for determining a subject's likelihood of responding
to and/or benefiting from administration of unacylated ghrelin.
Inventors: |
Van Der Lely; Aart Jan;
(Bergschenhoek, NL) ; Abribat; Thierry;
(Ste-Foy-Ies-Lyon, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Alize Pharma SAS |
ECULLY |
|
FR |
|
|
Assignee: |
Alize Pharma SAS
ECULLY
FR
|
Family ID: |
47780096 |
Appl. No.: |
14/364228 |
Filed: |
December 14, 2012 |
PCT Filed: |
December 14, 2012 |
PCT NO: |
PCT/IB12/02867 |
371 Date: |
June 10, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61576217 |
Dec 15, 2011 |
|
|
|
Current U.S.
Class: |
514/5.3 ; 435/29;
514/21.3; 514/21.4; 514/21.5; 514/21.6; 514/21.7; 514/21.8;
514/21.9; 514/6.7; 514/6.8 |
Current CPC
Class: |
A61K 38/12 20130101;
A61P 3/10 20180101; A61P 3/04 20180101; A61P 3/06 20180101; A61K
38/25 20130101; A61K 38/2264 20130101; C07K 7/06 20130101; G01N
2800/044 20130101; A61K 38/08 20130101; A61P 3/00 20180101; C07K
5/10 20130101; G01N 33/74 20130101; C07K 7/08 20130101; G01N
2333/62 20130101; G01N 2800/042 20130101; G01N 2800/52 20130101;
C07K 14/575 20130101 |
Class at
Publication: |
514/5.3 ;
514/6.8; 514/6.7; 514/21.3; 514/21.4; 514/21.5; 514/21.6; 514/21.7;
514/21.8; 514/21.9; 435/29 |
International
Class: |
C07K 14/575 20060101
C07K014/575; G01N 33/74 20060101 G01N033/74; C07K 5/10 20060101
C07K005/10; C07K 7/08 20060101 C07K007/08; C07K 7/06 20060101
C07K007/06 |
Claims
1. A method for decreasing ghrelin levels in a subject, comprising
administering an effective amount of unacylated ghrelin, a fragment
thereof, an analog thereof and/or pharmaceutically acceptable salts
thereof to the subject.
2. The method as defined in claim 1, wherein the ghrelin levels are
elevated circulating ghrelin levels.
3. (canceled)
4. The method as defined in claim 1, wherein the ghrelin levels are
associated with at least one of hyperglycemia, insulin resistance,
reduced fat utilization, adiposity, weight gain or suppression of
insulin secretion in the subject.
5. The method as defined in claim 1, wherein the subject suffers
from a condition selected from the group consisting of type 2
diabetes, hyperghrelinemia, obesity associated with insulin
resistance and Prader-Willi Syndrome and any combination
thereof.
6. The method as defined in claim 1, for decreasing a circulating
ghrelin/unacylated ghrelin ratio in the subject.
7. The method as defined in claim 6, wherein the circulating
ghrelin/unacylated ghrelin ratio is an elevated circulating
ghrelin/unacylated ghrelin ratio.
8-25. (canceled)
26. A method for preventing weight gain in a subject following
diet-induced weight loss, comprising administering an effective
amount of unacylated ghrelin, a fragment thereof, an analog thereof
and/or pharmaceutically acceptable salts thereof to the
subject.
27. The method as defined in claim 26, wherein the administration
of the unacylated ghrelin, the fragment thereof, the analog thereof
and/or the pharmaceutically acceptable salts thereof decreases the
ghrelin levels.
28. (canceled)
29. The method as defined in claim 1, wherein the unacylated
ghrelin has an amino acid sequence as set forth in SEQ ID NO:
1.
30. The method as defined in claim 1, wherein the unacylated
ghrelin fragment comprises an amino acid sequence as set forth in
SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:
10, SEQ ID NO: 11, SEQ ID NO: 12 or SEQ ID NO: 25.
31. The method as defined in claim 1, wherein the unacylated
ghrelin fragment is as set forth in SEQ ID NO: 6.
32. The method as defined in claim 1, wherein the unacylated
ghrelin fragment is as set forth in SEQ ID NO: 6 and comprises a
linker moiety.
33. The method as defined in claim 1, wherein the unacylated
ghrelin fragment is as set forth in SEQ ID NO: 25.
34. The method as defined in claim 1, wherein the effective amount
is from about 0.001 .mu.g/kg to about 10 .mu.g/kg.
35. The method as defined in claim 1, wherein effective amount is
from about 1 .mu.g/kg to about 1 mg/kg.
36-37. (canceled)
38. A pharmaceutical composition comprising an effective amount of
unacylated ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof and a pharmaceutically
acceptable diluent for decreasing ghrelin levels in a subject.
39-48. (canceled)
49. The pharmaceutical composition as defined in claim 38, wherein
the unacylated ghrelin fragment is as set forth in SEQ ID NO:
25.
50-58. (canceled)
59. A method for screening within a population of subjects
suffering from diabetes, Prader-Willi Syndrome, obesity, insulin
resistance or hyperphagia, which subjects within the population are
susceptible of benefiting from an administration of unacylated
ghrelin, a fragment thereof or an analog thereof, comprising:
determining a level of circulating ghrelin from the subjects of the
population; processing the level of circulating ghrelin at least in
part based on a reference level of circulating ghrelin to derive
information conveying whether the level of circulating ghrelin is
elevated; and causing conveyance of the information to a recipient
for determining the subject's susceptibility of benefiting from
administration of unacylated ghrelin, a fragment thereof or an
analog thereof.
60. The method of claim 59, further comprising: determining a ratio
of circulating ghrelin/unacylated ghrelin from the subjects of the
population; processing the ratio of circulating ghrelin/unacylated
ghrelin at least in part based on a reference level of circulating
ghrelin/unacylated ghrelin to derive information conveying whether
the ratio of circulating ghrelin/unacylated ghrelin is elevated;
and causing conveyance of the information to a recipient for
determining the subject's susceptibility of benefiting from
administration of unacylated ghrelin.
61. The method as defined claim claim 59, further comprising
administering a therapeutically effective amount of unacylated
ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof to the subjects that are
susceptible of benefiting from administration of unacylated
ghrelin.
62. (canceled)
63. The method as defined in claim 60, wherein the ratio of
circulating ghrelin/unacylated ghrelin is elevated when it is above
the normal ratio of circulating ghrelin/unacylated ghrelin.
64. The method as defined in claim 59, wherein the subjects of the
population suffer from Type 2 diabetes.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U.S.
provisional patent application No.
[0002] 61/576,217, filed Dec. 15, 2011, the content of which is
herein incorporated in its entirety by reference.
FIELD OF THE INVENTION
[0003] This invention relates to the use of unacylated ghrelin,
fragments and/or analogs thereof for modulating ghrelin levels
and/or ghrelin/unacylated ghrelin ratio in a subject wherein such
modulation is beneficial to the subject. The invention also relates
to the composition comprising unacylated ghrelin, fragments and/or
analogs thereof modulating ghrelin levels and/or ghrelin/unacylated
ghrelin ratio in a subject wherein such modulation is beneficial to
the subject. The invention further relates to the use of ghrelin
level and/or ghrelin/unacylated ghrelin ratio as biomarkers for
determining a subject's likelihood of responding to and/or
benefiting from administration of unacylated ghrelin.
BACKGROUND
[0004] Ghrelin (also referred as "acylated ghrelin" or abbreviated
as "AG") is a 28 amino acid peptide, purified and identified from
rat stomach and characterized by the presence of an n-octanoyl
modification on the Ser3 residue (Ref. 1). Acylation of ghrelin is
catalyzed by the enzyme ghrelin O-acyl transferase (GOAT). The
expression of GOAT is mostly in the stomach and intestine. Ghrelin
is the endogenous ligand of the growth hormone (GH) secretagogue
receptor (GHSR-1a) (Refs. 2, 3). Ghrelin is now mostly recognized
as a potent orexigenic factor stimulating food intake and
modulating energy expenditure (Refs. 4, 5 and 6). At the peripheral
level, Ghrelin exerts probably its major physiological action
regulating glucose and lipid metabolism (Ref. 7). In fact, ghrelin
has a diabetogenic action (Ref. 8) and suppresses
glucose-stimulated insulin secretion and deteriorates glucose
tolerance (Ref. 9). As such, elevated plasma ghrelin is of
relevance in certain disorders of the metabolism and growth such as
in diabetes and obesity. Elevated plasma ghrelin levels have also
been demonstrated amongst adults and children with Prader-Willi
Syndrome (PWS) (Ref. 10 and 11). PWS is a genetic obesity syndrome
associated in most patients with GH deficiency. Children with PWS
present a rapid weight gain along with a voracious appetite.
Studies on the involvement of ghrelin in PWS have provided a
significant rationale that the hyperphagia observed in PWS is
positively correlated with elevated ghrelin levels, consistent with
the known orexigenic effect of ghrelin (Ref. 12).
[0005] Unacylated ghrelin (also referred as "des-acyl ghrelin" or
abbreviated as "UAG"), is the non-acylated form of ghrelin. Its
concentration in plasma and tissue is higher compared to ghrelin.
UAG has long been considered as a product with no physiological
role as it fails to bind the only known ghrelin receptor GHSR-1a at
physiological concentrations and has no physiological effect on GH
secretion (Ref. 15). However, UAG is a biologically active peptide,
particularly at the metabolic level and its administration has been
shown to induce a negative energy balance by decreasing food intake
and delaying gastric emptying (Ref. 16). Over-expression of UAG in
mice results in a decrease in fat accumulation with an increase in
insulin sensitivity and glucose tolerance (Refs. 16 and 17).
[0006] UAG has been shown to prevent the hyperglycemic effects of
ghrelin, when administered concomitantly, in healthy volunteers,
see in particular U.S. Pat. No. 7,825,090, herein incorporated in
its entirety by reference. This initial observation was followed by
several reports on the anti-diabetogenic potential of UAG (Refs.
18, 19, 30, 31 and 32).
[0007] In vitro, in vivo and clinical evidence indicate that UAG
prevents the diabetogenic effects of ghrelin in healthy volunteers
and in GH-deficient patients (Refs. 18 and 19). It inhibits both
basal and ghrelin-induced glucose secretion by human hepatocytes
(Ref. 31). In rats, UAG enhances portal insulin response to glucose
(Ref. 32) and reduces fat deposition and triglycerides levels, as
observed in transgenic mice overexpressing UAG (Ref. 16). In vitro,
UAG stimulates insulin secretion from insulinoma cells (Ref. 32)
and promotes proliferation and inhibits apoptosis of beta cells
(Ref. 33).
[0008] The anti-diabetogenic effects and ghrelin-antagonizing
effects of UAG, fragments and analogs thereof have been reported in
U.S. Pat. No. 7,485,620; U.S. Pat. No. 8,222,217; U.S. Pat. No.
8,318,664 and in WO 2008/145749, which are all in their entirety
incorporated herein by reference.
[0009] Recent experiments on circulating angiogenic cells (CAC)
indicates that UAG beneficially impacts the vascular remodeling
process which is known to be impaired in type 2 diabetes patients.
The effects of UAG on CAC have been reported in U.S. Patent
Application Serial Number 2010/0016226 and in WO 2009/150214,
herein incorporated in their entirety by reference.
[0010] Obese mice and humans have been reported to present lower
UAG levels than normal weight subjects, indicating that obesity
might be correlated with a relative UAG deficiency (Refs. 34, 35
and 21). It has been observed that insulin-resistant obese subjects
have an elevated AG/UAG ratio when compared to insulin-sensitive
obese subjects (Refs. 20 and 22).
[0011] Treatments that target ghrelin and the GHS-R (i.e., ghrelin
antagonists) have been suggested as attractive pharmacologic
avenues to fight against obesity and other conditions, disorders
and diseases associated with ghrelin. Several GHS-R ligands and
anti-obesity vaccines have been proposed (Ref. 24). Other
pharmacological approaches inducing antibodies against ghrelin,
ghrelin enantiomers and inhibition of ghrelin acyl-transferase
(GOAT) (Ref. 25) have been investigated; however, due to lack of
efficacy, non-selectivity and lack of sustained weight loss, these
pharmacological approaches have not yet reached the market (Ref.
26).
[0012] Therefore, there exists a need in the art for an efficient
and more direct way of modulating circulating ghrelin levels and/or
circulating ghrelin/unacylated ghrelin ratio in subjects wherein
such modulation is beneficial to the subject and for more efficient
ways of identifying those subjects that can benefit from modulation
of ghrelin levels and ghrelin/unacylated ghrelin ratio.
SUMMARY OF THE INVENTION
[0013] According to one aspect, the present invention provides a
method for decreasing ghrelin levels in a subject, comprising
administering an effective amount of unacylated ghrelin, a fragment
thereof, an analog thereof and/or pharmaceutically acceptable salts
thereof to the subject.
[0014] According to another aspect, the present invention provides
a method for decreasing ghrelin levels and ghrelin/unacylated
ghrelin ratio in a subject, comprising administering an effective
amount of unacylated ghrelin, a fragment thereof, an analog thereof
and/or pharmaceutically acceptable salts thereof to the
subject.
[0015] According to another aspect, the present invention provides
a method for ameliorating a symptom associated with ghrelin levels
in a subject, comprising administering an effective amount of
unacylated ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof to the subject.
[0016] According to another aspect, the present invention provides
a method for ameliorating a symptom associated with ghrelin levels
and with ghrelin/unacylated ghrelin ratio in a subject, comprising
administering an effective amount of unacylated ghrelin, a fragment
thereof, an analog thereof and/or pharmaceutically acceptable salts
thereof to the subject.
[0017] According to another aspect, the present invention provides
a method for ameliorating and/or treating a condition caused by
elevated ghrelin levels in a subject, comprising administering to a
subject having the condition an effective amount of unacylated
ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof.
[0018] According to another aspect, the present invention provides
a method for ameliorating and/or treating a condition cause by
elevated ghrelin levels and elevated ghrelin/unacylated ghrelin
ratio in a subject, comprising administering to a subject having
the condition an effective amount of unacylated ghrelin, a fragment
thereof, an analog thereof and/or pharmaceutically acceptable salts
thereof.
[0019] According to another aspect, the present invention provides
a method for preventing weight gain in a subject following
diet-induced weight loss, comprising administering an effective
amount of unacylated ghrelin, a fragment thereof, an analog thereof
and/or pharmaceutically acceptable salts thereof to the
subject.
[0020] According to another aspect, the present invention provides
a pharmaceutical composition comprising an effective amount of
unacylated ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof and a pharmaceutically
acceptable diluent for decreasing ghrelin levels in a subject.
[0021] According to another aspect, the present invention provides
a pharmaceutical composition comprising an effective amount of
unacylated ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof and a pharmaceutically
acceptable diluent for ameliorating symptoms associated with
ghrelin levels in a subject.
[0022] According to another aspect, the present invention provides
a pharmaceutical composition comprising an effective amount of
unacylated ghrelin, a fragment thereof, an analog thereof and/or
pharmaceutically acceptable salts thereof and a pharmaceutically
acceptable diluent for preventing weight gain in a subject
following diet-induced weight loss.
[0023] According to another aspect, the present invention provides
the use of an effective amount of unacylated ghrelin, a fragment
thereof, an analog thereof and/or pharmaceutically acceptable salts
thereof and a pharmaceutically acceptable diluent for decreasing
ghrelin levels in a subject.
[0024] According to another aspect, the present invention provides
the use of an effective amount of unacylated ghrelin, a fragment
thereof, an analog thereof and/or pharmaceutically acceptable salts
thereof and a pharmaceutically acceptable diluent for ameliorating
symptoms associated with ghrelin levels in a subject.
[0025] According to another aspect, the present invention provides
the use of an effective amount of unacylated ghrelin, a fragment
thereof, an analog thereof and/or pharmaceutically acceptable salts
thereof and a pharmaceutically acceptable diluent for preventing
weight gain in a subject following diet-induced weight loss.
[0026] According to another aspect, the present invention provides
a method for screening within a population of subjects suffering
from diabetes, Prader-Willi Syndrome, obesity, insulin resistance
or hyperphagia, which subjects within the population are
susceptible of benefiting from an administration of unacylated
ghrelin, a fragment thereof or an analog thereof, comprising:
determining a level of circulating ghrelin from the subjects of the
population; processing the level of circulating ghrelin at least in
part based on a reference level of circulating ghrelin to derive
information conveying whether the level of circulating ghrelin is
elevated; and causing conveyance of the information to a recipient
for determining the subject's susceptibility of benefiting from
administration of unacylated ghrelin.
[0027] According to another aspect, the present invention provides
a method for screening within a population of subjects suffering
from diabetes, Prader-Willi Syndrome, obesity, insulin resistance
or hyperphagia, which subjects are susceptible of benefiting from
an administration of unacylated ghrelin, a fragment thereof or an
analog thereof, comprising: determining a level of circulating
ghrelin and a ratio of circulating ghrelin/unacylated ghrelin from
the subjects of the population; processing the level of circulating
ghrelin and the ratio of circulating ghrelin/unacylated ghrelin at
least in part based on a reference level of circulating ghrelin and
a reference ratio of circulating ghrelin/unacylated ghrelin to
derive information conveying whether the level of circulating
ghrelin and the ratio of circulating ghrelin/unacylated ghrelin are
elevated; and causing conveyance of the information to a recipient
for determining the subject's susceptibility of benefiting from
administration of unacylated ghrelin.
BRIEF DESCRIPTION OF THE FIGURES
[0028] FIG. 1 is a schematic representation of a study protocol
involving Type 2 Diabetes Mellitus (T2DM) subjects according to one
embodiment of the present invention. SBM refers to Standard
Breakfast Meal.
[0029] FIGS. 2A and 2B are graphs illustrating the effect of UAG
infusion on AG serum levels in T2DM subjects. In FIG. 2A, AG serum
levels in pg/ml were measured following placebo or UAG
administration before and one hour after SBM. In FIG. 2B, UAG serum
levels in pg/ml were measured following placebo or UAG
administration before and one hour after SBM.
[0030] FIGS. 3A and 3B are graphs illustrating the mean
post-prandial glucose levels in T2DM subjects as measured with a
continuous glucose monitoring device (CGMS.RTM. iPro.TM. Continuous
Glucose Recorder, Medtronic trading, The Netherlands). FIG. 3A
shows the mean absolute glucose levels after SBM and following
placebo, UAG 3 mcg/kg/h and UAG 10 mcg/kg/h infusions. Repeated
measures ANOVA p<0.0001; Bonferroni's Multiple Comparisons
placebo vs. 3 mcg NS; placebo vs. 10 mcg p<0.001; 3 mcg vs. 10
mcg p<0.001. FIG. 3B shows the mean t0-t180 glucose levels for
the three treated groups.
[0031] FIGS. 4A and 4B are graphs illustrating the mean
post-prandial glucose levels in T2DM subjects. FIG. 4A shows the
change in glucose levels from pre-meal baseline following placebo,
UAG 3 mcg/kg/h and UAG 10 mcg/kg/h infusions. Repeated measures
ANOVA p<0.0001; Bonferroni's Multiple Comparisons placebo vs. 3
mcg p<0.001; placebo vs. 10 mcg p<0.001; 3 mcg vs. 10 mcg
p<0.05. FIG. 4B shows the mean t0-t180 glucose levels for the
three treated groups.
[0032] FIGS. 5A and 5B are graphs illustrating the peak plasma
glucose levels after SBM in the eight subjects of the study
following placebo, UAG 3 mcg/kg/h and UAG 10 mcg/kg/h infusions.
Wilcoxon matched-pairs signed rank test; *: 10 mcg vs. Placebo,
p<0.05.
[0033] FIGS. 6A, 6B and 6C are graphs indicating the existence of a
correlation between fasting basal AG and/or UAG concentrations and
glycemic response to UAG administration. The graph in FIG. 6A
illustrates the correlation between fasting basal AG levels and
change (following UAG vs. placebo administration) in peak glucose
levels after SBM. The graph in FIG. 6B illustrates the correlation
between fasting basal AG levels and change (following UAG vs.
placebo administration) in AUC glucose levels after SBM using iPro
continuous glucose measurements. The graph in FIG. 6C illustrates
the correlation between the ratio of fasting basal AG over UAG
levels and change (following UAG vs. placebo administration) in AUC
glucose levels after SBM using iPro continuous glucose
measurements.
[0034] FIG. 7A is a schematic representation of a
Hyperinsulinemic-Euglycemic Clamp study protocol in T2DM subjects
according to a further embodiment of the present invention.
[0035] FIG. 7B is a graph illustrating the effects of UAG on the
M-index, reflective of insulin sensitivity, during the protocol as
schematized in FIG. 7A. The change in M-index from baseline was
measured following placebo and UAG infusions. *: p<0.05,
One-tailed Mann Whitney test.
[0036] FIGS. 7C and 7D are graphs illustrating the effects of a
short UAG infusion period on basal AG levels in T2DM subjects. FIG.
7C shows circulating AG levels before UAG infusion and following a
2.5 hour UAG infusion. FIG. 7D shows the AG change from baseline
after a 2.5 hour UAG infusion ([AG] level at 12:00--[AG] levels at
9:30). Two-tailed Wilcoxon matched-pairs signed rank test; *:
p<0.05; **: p<0.01.
[0037] FIG. 8 is a graph illustrating the effects of cyclic UAG
fragment (6-13) on AG-induced food intake over the indicated study
period. *p<0.001: Kruskal-Wallis One Way ANOVA. Differences
between groups were evaluated by the Dunn's test.
DETAILED DESCRIPTION
[0038] The present invention stems from, but is not limited to, the
findings by the Inventors that administration of UAG decreases
levels of circulating AG in subjects with T2DM. The present
invention further stems from the findings that the higher the level
of basal AG, the more important are the effects of UAG on reducing
AG levels and on reducing the deleterious effects associated with
AG levels such as, for example, obesity, hyperglycemia, insulin
resistance, fat deposition, hyperphagia and obesity associated with
insulin resistance. The Inventors have also found that the higher
the ratio of circulating AG/UAG, the more efficient is UAG in
decreasing such ratio and in suppressing the deleterious effects
associated with AG/UAG ratio.
[0039] In view of this, circulating AG level and circulating AG/UAG
ratio may each be used as biomarkers for identifying a subject's
likelihood of responding to and/or benefiting from administration
of UAG. These biomarkers may thus be used for identifying within a
population of subjects suffering from a condition such as, but not
limited to, obesity, diabetes, insulin resistance, Prader-Willi,
hyperphagia and hyperghrelinemia, which of the subjects are likely
to respond to and/or benefit from administration of UAG. The higher
the circulating AG levels and/or the higher the circulating AG/UAG
ratio in a subject, the more this subject is likely to respond to
and/or benefit from the administration of UAG.
[0040] To this date, studies have reported that UAG counteracts the
peripheral actions of ghrelin on, for example, glucose and insulin
metabolisms. The present study provides the first evidence that
administration of UAG also suppresses circulating ghrelin levels
and provides the first evidence of the existence of a correlation
between the level of circulating AG and the efficacy of UAG in
improving metabolic parameters affected by AG levels and/or by
AG/UAG ratio.
[0041] The surprising demonstrations presented therein allow to
expand the applications and the indications for which unacylated
ghrelin can be used so as to include the facilitation, amelioration
and/or treatment of conditions that result from AG levels and/or
AG/UAG ratio.
[0042] These demonstrations also allow to expand the applications
and the indications for which unacylated ghrelin can be used so as
to include the facilitation, amelioration and/or treatment of
conditions that result from elevated AG levels and/or elevated
AG/UAG ratio.
[0043] As used herein, the expression "elevated AG level(s)" refers
to a level of circulating AG that is above the AG level observed in
normal and/or healthy subjects. In some implementations, the
expression "elevated AG level(s)" refers to a level of circulating
AG at which one or more deleterious physiological symptoms
associated with AG appear, persist or are worsen in a subject.
[0044] As used herein, the expression "elevated AG/UAG ratio"
refers to a ratio of circulating AG/UAG that is above the AG/UAG
ratio observed in normal and/or healthy subjects. In some
implementations, the expression "elevated AG/UAG ratio" refers to a
ratio of circulating AG/UAG at which one or more deleterious
physiological symptoms associated with the AG/UAG ratio appear or
persist or are worsen in a subject.
[0045] It is to be understood that several factors may affect the
levels of circulating ghrelin and unacylated ghrelin in normal
subjects. Examples of such factors include, but are not limited to,
gender, age, fitness, body mass index (BMI), eating habits,
etc.
[0046] As used herein, the expression "inhibition of ghrelin"
refers to an impairment of the biological activity of ghrelin which
occurs due to a decrease in ghrelin levels and/or due to an
impairment of its biological activity.
[0047] A person skilled in the art will be familiar with the
techniques and assays for measuring AG and UAG levels in a subject.
Such techniques may include techniques that involve the use of
protease inhibitors such as 4-(2-aminoethyl) benzenesulfonyl
fluoride hydrochloride (AEBSF) or other cocktail of protease
inhibitors.
[0048] In one implementation of this embodiment, an obese subject
is characterized as having a body weight approximately 20%,
approximately 25%, approximately 30% or greater than the normal
body weight for said subject. Normal body weight may be determined
by a comparison of the weight of the subject at a prior point in
time, such as when AG levels were normal and/or when AG/UAG ratio
was normal, or by a comparison of the AG levels and/or AG/UAG ratio
of the subject as compared to averages of other subjects of a
similar age and/or condition.
[0049] In another implementation of this embodiment, an overweight
subject is characterized as having a body weight approximately 5%
greater to approximately 20% greater than the normal body weight
for said subject. Normal body weight may be determined by a
comparison of the weight of the subject at a prior point in time,
such as as when AG levels were normal and/or when AG/UAG ratio was
normal, or by a comparison of the AG levels and/or AG/UAG ratio as
compared to averages of other subjects of a similar age and/or
condition.
[0050] In another implementation of this embodiment, a normal
subject is characterized as having a body weight approximately 5%
greater than to approximately 5% less than the normal body weight
for said subject. Normal body weight may be determined by a
comparison of the weight of the subject at a prior point in time,
such as when AG levels were normal and/or when AG/UAG ratio was
normal, or by a comparison of the AG levels and/or AG/UAG ratio as
compared to averages of other subjects of a similar age and/or
condition. A normal weight subject may have a BMI in the
approximate range of 19-22.
[0051] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
skill in the art to which the invention pertains. [0052] i)
Unacylated ghrelin, fragments and analogs thereof
[0053] The terms "unacylated ghrelin", "des-acyl ghrelin" and the
abbreviation "UAG" are intended to mean peptides that have the
amino acid sequence specified in SEQ ID NO: 1 which amino acid
sequence is:
TABLE-US-00001 (SEQ ID NO: 1)
Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-
Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-
Leu-Gln-Pro-Arg
[0054] Unacylated ghrelin may also be referred to as UAG
(1-28).
[0055] Naturally-occurring variations of UAG include peptides that
contain substitutions, additions or deletions of one or more amino
acids which result due to discrete changes in the nucleotide
sequence of the encoding ghrelin gene or alleles thereof or due to
alternative splicing of the transcribed RNA. It is understood that
the changes do not substantially affect the properties,
pharmacological and biological characteristics of unacylated
ghrelin variants.
[0056] Those peptides may be in the form of salts. Particularly the
acidic functions of the molecule may be replaced by a salt
derivative thereof such as, but not limited to, a trifluoroacetate
or an acetate salt.
[0057] By "peptide", "polypeptide" or "protein" is meant any chain
of amino acids, regardless of length or post-translational
modification (e.g., glycosylation or phosphorylation), or chemical
modification, or those containing unnatural or unusual amino acids
such as D-Tyr, ornithine, amino-adipic acid. The terms are used
interchangeably in the present application.
[0058] The expressions "fragments" and "fragments thereof" refer to
amino acid fragments of a peptide such as UAG.
[0059] Fragments of UAG are shorter than the amino acid sequence
depicted in SEQ ID NO: 1, therefore are shorter than 28 amino acid
residues. Fragments of UAG may therefore be 27, 26, 25, 24, 23, 22,
21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 or 4
amino acid residues in length. For example, fragments of UAG may
have the amino acid sequences depicted in Table 1 below:
TABLE-US-00002 TABLE 1 SEQ ID Fragment NO: Amino Acid Sequence UAG
(1-14) 2 Gly-Ser-Ser-Phe-Leu- Ser-Pro-Glu-His-Gln- Arg-Val-Gln-Gln
UAG (1-18) 3 Gly-Ser-Ser-Phe-Leu- Ser-Pro-Glu-His-Gln-
Arg-Val-Gln-Gln-Arg- Lys-Glu-Ser UAG (1-5) 4 Gly-Ser-Ser-Phe-Leu
UAG (17-28) 5 Glu-Ser-Lys-Lys-Pro- Pro-Ala-Lys-Leu-Gln- Pro-Arg UAG
(6-13) 6 Ser-Pro-Glu-His-Gln- Arg-Val-Gln UAG (8-13) 7
Glu-His-Gln-Arg-Val- Gln UAG (8-12) 8 Glu-His-Gln-Arg-Val UAG
(6-18) 9 Ser-Pro-Glu-His-Gln- Arg-Val-Gln-Gln-Arg- Lys-Glu-Ser UAG
(8-11) 10 Glu-His-Gln-Arg UAG (9-12) 11 His-Gln-Arg-Val UAG (9-11)
29 His-Gln-Arg UAG (14-1) 30 Gln Gln Val Arg Gln His Glu Pro Ser
Leu Phe Ser Ser Gly
[0060] Any other fragments of UAG that preserve the biological
activity of UAG are encompassed by the present invention. Some UAG
fragments have been reported in U.S. Pat. No. 8,222,217; U.S. Pat.
No. 8,318,664 and in WO/2008/145749, incorporated herein in their
entirety by reference, wherein it has been demonstrated that the
smallest UAG fragment to retain the biological activity of UAG is
UAG (9-12) depicted herein as SEQ ID NO: 11.
[0061] In one embodiment, the polypeptides such as UAG, fragments
or analogs thereof, are used in a form that is "purified",
"isolated" or "substantially pure". The polypeptides are
"purified", "isolated" or "substantially pure" when they are
separated from the components that naturally accompany them.
Typically, a compound is substantially pure when it is at least
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, by
weight, of the total material in a sample.
[0062] The expressions "analog of unacylated ghrelin", "analog of
fragments of unacylated ghrelin" and "analogs thereof" refer to
both structural and functional analogs of UAG or fragments thereof
which are, inter alia, capable of replacing UAG in the biological
function of UAG as described in the present application, such as,
but not limited to modulate AG; inhibit AG; decrease circulating AG
levels; decrease circulating elevated AG levels; decrease
circulating AG/UAG ratio; decrease circulating elevated AG/UAG
ratio; ameliorate the symptoms induced by AG levels and/or AG/UAG
levels; facilitate, prevent and/or treat conditions associated with
circulating AG and/or circulating AG/UAG ratio and facilitate,
prevent and/or treat conditions associated with elevated
circulating AG and/or elevated circulating AG/UAG ratio. Some
analogs of UAG have been reported in U.S. Pat. No. 8,222,217; U.S.
Pat. No. 8,318,664 and in WO/2008/145749, incorporated herein in
their entirety by reference.
[0063] Simple structural analogs comprise peptides showing homology
with UAG as set forth in SEQ ID NO: 1 or homology with any fragment
thereof. An example of an analog of AG is an isoform of Ghrelin-28,
des Gln-14 Ghrelin (a 27 amino acid peptide possessing serine 3
modification by n-octanoic acid) which is shown to be present in
stomach. It is functionally identical to AG in that it binds to
GHSR-1a with similar binding affinity, elicits Ca.sup.2+ fluxes in
cloned cells and induces GH secretion with similar potency as
Ghrelin-28. It is expected that UAG also has a des Gln-14 UAG that
is functionally identical to UAG.
[0064] Preferred analogs of UAG and preferred analogs of fragments
of UAG are those that vary from the native UAG sequence or from the
native UAG fragment sequence by conservative amino acid
substitutions; i.e., those that substitute a residue with another
of like characteristics. Typical substitutions include those among
Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues
Asp and Glu; among Asn and Gln; among the basic residues Lys and
Arg; and among the aromatic residues Phe and Tyr. Particularly
preferred are analogs in which several, for example, but not
limited to, 5-10, 1-5, or 1-2 amino acids are substituted, deleted,
or added in any combination. For example, the analogs of UAG may
differ in sequence from UAG by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
amino acid substitutions (preferably conservative substitutions),
deletions, or additions, or combinations thereof.
[0065] There are provided herein, analogs of the peptides of the
invention that have at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98% or 99% sequence homology or sequence
identity with the amino acid sequences described herein over its
full length, and sharing at least one of the metabolic effects or
biological activity of UAG. A person skilled in the art would
readily identify an analog sequence of unacylated ghrelin or an
analog sequence of a fragment of unacylated ghrelin.
[0066] Examples of analogs of UAG are provided in Table 2
below:
TABLE-US-00003 TABLE 2 SEQ ID Analog NO: Amino acid sequence (Asp)8
UAG (6-13)NH.sub.2 12 Ser-Pro-Asp-His- Gln-Arg-Val-Gln (Lys)11 UAG
(6-13)NH.sub.2 13 Ser-Pro-Glu-His- Gln-Lys-Val-Gln (Gly)6 UAG
(6-13)NH.sub.2 14 Gly-Pro-Glu-His- Gln-Arg-Val-Gln (Ala)6 UAG
(6-13)NH.sub.2 15 Ala-Pro-Glu-His- Gln-Arg-Val-Gln (Ala)7 UAG
(6-13)NH.sub.2 16 Ser-Ala-Glu-His- Gln-Arg-Val-Gln (Ala)8 UAG
(6-13)NH.sub.2 17 Ser-Pro-Ala-His- Gln-Arg-Val-Gln (Ala)9 UAG
(6-13)NH.sub.2 18 Ser-Pro-Glu-Ala- Gln-Arg-Val-Gln (Ala)10 UAG
(6-13)NH.sub.2 19 Ser-Pro-Glu-His- Ala-Arg-Val-Gln (Ala)11 UAG
(6-13)NH.sub.2 20 Ser-Pro-Glu-His- Gln-Ala-Val-Gln (Ala)12 UAG
(6-13)NH.sub.2 21 Ser-Pro-Glu-His- Gln-Arg-Ala-Gln (Ala)13 UAG
(6-13)NH.sub.2 22 Ser-Pro-Glu-His- Gln-Arg-Val-Ala (Acetyl-Ser)6
UAG 23 Ac-Ser-Pro-Glu- (6-13)NH.sub.2 His-Gln-Arg-Val- Gln
(Acetyl-Ser)6, (DPro)7 24 Ac-Ser-pro-Glu- UAG (6-13)NH.sub.2
His-Gln-Arg-Val- Gln Cyclo (6-13) UAG (also 25 Ser-Pro-Glu-His-
referred to as cyclic Gln-Arg-Val-Gln UAG (6-13)) (cycl) Cyclo
(8,11), Lys 11, 26 Ser-Pro-Glu-His- UAG (6-13)amide
Gln-Lys-Val-Gln- amide Cyclo (8,11), Acetyl- 27 Ac-Ser-Pro-Glu-
Ser6, Lys 11, UAG His-Gln-Lys-Val- (6-13)-amide Gln (cycl)
Acetyl-Ser6, Lys 11, 28 Ac-Ser-Pro-Glu- UAG (6-13)NH.sub.2
His-Gln-Lys-Val- Gln-NH.sub.2
[0067] Analogs of UAG or analogs of fragments thereof are, for
example, analogs obtained by alanine scans, by substitution with
D-amino acids or with synthetic amino acids or by cyclization of
the peptide. Analogs of UAG or fragments thereof may comprise a
non-naturally encoded amino acid, wherein the non-naturally
encoding amino acid refers to an amino acid that is not one of the
common amino acids or pyrrolysine or selenocysteine, or an amino
acid that occur by modification (e.g. post-translational
modification) of naturally encoded amino acid (including, but not
limited to, the 20 common amino acids or pyrrolysine and
selenocysteine) but are not themselves incorporated into a growing
polypeptide chain by the translation complex. Examples of such
non-naturally-occurring amino acids include, but are not limited
to, N-acetylglucosaminyl-L-serine, N-acetylglucosaminyl-L-threonine
and O-phosphotyrosine.
[0068] As used herein, the term "modified" refers to any changes
made to a given polypeptide, such as changes to the length of the
polypeptide, the amino acid sequence, chemical structure,
co-translational modification, or post-translational modification
of a polypeptide.
[0069] The term "post-translational modification" refers to any
modification of a natural or non-natural amino acid that occurs to
such an amino acid after it has been incorporated into a
polypeptide chain. The term encompasses, by way of example only,
co-translational in vivo modifications, co-translational in vitro
modifications (such as in cell-free translation system),
post-translational in vivo modifications, and post-translational in
vitro modifications.
[0070] Examples of post-translational modifications are, but are
not limited to, glycosylation, acetylation, acylation, amidation,
carboxylation, phosphorylation, PEGylation, addition of salts,
amides or esters, in particular C-terminal esters, and N-acyl
derivatives of the peptides of the invention. The types of
post-translational modifications are well known.
[0071] Certain peptides according to the present invention may also
be in cyclic form, such that the N- or C-termini are linked
head-to-tail either directly, or through the insertion of a linker
moiety, such moiety itself generally comprises one or more amino
acid residues as required to join the backbone in such a manner as
to avoid altering the three-dimensional structure of the peptide
with respect to the non-cyclic form. Such peptide derivatives may
have improved stability and bioavailability relative to the
non-cyclized peptides.
[0072] Examples of cyclic peptides of the present invention
include: cyclic UAG (1-14), cyclic UAG (1-18), cyclic UAG (17-28),
cyclic UAG (6-13), cyclic UAG (8-13), cyclic UAG (8-12), cyclic UAG
(8-11), cyclic UAG (9-12) and cyclic UAG (9-11) as well as the
peptides identified in Table 2.
[0073] Methods for cyclizing peptides are well known in the art and
for example may be accomplished by disulfide bond formation between
two side chain functional groups, amide or ester bond formation
between one side chain functional group and the backbone a-amino or
carboxyl function, amide or ester bond formation between two side
chain functional groups, or amide bond formation between the
backbone .alpha.-amino and carboxyl functions. These cyclization
reactions have been traditionally carried out at high dilution in
solution. Cyclization is commonly accomplished while the peptide is
attached to the resin. One of the most common ways of synthesizing
cyclic peptides on a solid support is by attaching the side chain
of an amino acid to the resin. Using appropriate protection
strategies, the C-and N-termini can be selectively deprotected and
cyclized on the resin after chain assembly. This strategy is widely
used, and is compatible with either tert-butyloxycarbonyl (Boc) or
9-fluorenylmethoxycarbonyl (Fmoc) protocols. However, it is
restricted to peptides that contain appropriate side chain
functionality to attach to the solid support. A number of
approaches may be used to achieve efficient synthesis of cyclic
peptides. One procedure for synthesizing cyclic peptides is based
on cyclization with simultaneous cleavage from the resin. After an
appropriate peptide sequence is assembled by solid phase synthesis
on the resin or a linear sequence is appended to resin, the
deprotected amino group can react with its anchoring active linkage
to produce protected cyclic peptides. In general, a final
deprotection step is required to yield the target cyclic
peptide.
[0074] Lactamazation, a form of cyclization, may be performed to
form a lactam bridge using Fmoc synthesis, amino acids with
different protecting groups at the lateral chains may be
introduced, such as, but not limited to, aspartic acid (or
glutamic) protected with allyl ester at the beta ester (or gamma
ester for glutamic acid) and lysine protected with allyloxy
carbamate at the N-.epsilon.. At the end of the synthesis, with the
N-terminus of the peptide protected with Fmoc, Boc or other
protecting group different from Alloc, the allyl and alloc
protecting groups of aspartic acid and lysine may be deprotected
with, for example, palladium (0) followed by cyclization using
PyAOP (7-Azabenzotriazol-1-yloxytris(pyrrolidino)
phosphonium-hexafluorophosphate) to produce the lactam bridge.
[0075] Unless otherwise indicated, an amino acid named herein
refers to the L-form. Well recognized abbreviations in the art will
be used to describe amino acids, including levorotary amino acids
(L-amino acids or L or L-form) and dextrorotatory amino acids
(D-amino acids or D or D-form), Alanine (Ala or A), Arginine (Arg
or R), Asparagine (Asn or N), Aspartic acid (Asp or D), Cysteine
(Cys or C), Glutamic acid (Glu or E), Glutamine (Gln or Q), Glycine
(Gly or G), Histidine (His or H), Isoleucine (Ile or I), Leucine
(Leu or L), Lysine (Lys or K), Methionine (Met or M), Phenylalanine
(Phe or F), Proline (Pro or P), Serine (Ser or S), Threonine (Thr
or T), Tryptophan (Trp or W), Tyrosine (Tyr or Y) and Valine (Val
or V). An L-amino acid residue within the native peptide sequence
may be altered to any one of the 20 L-amino acids commonly found in
proteins or any one of the corresponding D-amino acids, rare amino
acids, such as, but not limited to, 4-hydroxyproline or
hydroxylysine, or a non-protein amino acid, such as P-alanine or
homoserine.
[0076] UAG peptides or fragments or analogs thereof may also be
part of a fusion protein. It is often advantageous to include an
additional amino acid sequence such as a signal sequence which
contains for example secretory or leader sequences, pro-sequences,
linker sequences which, inter alia, aid in purification such as
multiple histidine residues (HA-tag), or an additional sequence for
stability during recombinant production. The additional amino acids
or sequence may be linked to at the N-terminal or at the C-terminal
of the polypeptide or may be linked to any amino acid of the
sequences located between the N- and the C-terminal to give rise
the UAG peptides or fragment or analogs thereof having a linker
moiety.
[0077] Any other analogs of UAG or fragments thereof or any other
modified UAG or fragments thereof that preserve the biological
activity of the full length UAG are encompassed by the present
invention.
[0078] General methods and synthetic strategies used in providing
functional and structural analogs of UAG or fragments thereof are
commonly used and well known in the art and are described in
publications such as: "Peptide synthesis protocols" ed, M. W.
Pennigton & B. M. Dunn. Methods in Molecular Biology. Vol 35.
Humana Press, NJ.,1994; "Solid phase peptide synthesis" by Stewart
and Young, W. h Freeman & Co., San Francisco, 1969 and Erickson
and Merrifield; and "The Proteins" Vol. 2, p. 255 et seq. (Ed.
Neurath and Hill), Academic Press, New York, 1976.
[0079] As used herein, the term "homology" refers to sequence
similarity between two peptides while retaining an equivalent
biological activity. Homology can be determined by comparing each
position in the aligned sequences. A degree of homology between
amino acid sequences is a function of the number of identical or
matching amino acids at positions shared by the sequences so that a
"homologous sequence" refers to a sequence sharing homology and an
equivalent function or biological activity. Assessment of percent
homology is known by those of skill in the art.
[0080] Methods to determine homology, identity and similarity of
peptides are codified in publicly available computer programs.
Preferred computer program methods to determine identity and
similarity between two sequences include, but are not limited to,
the GCG program package, BLASTP, BLASTN, and FASTA. The BLAST X
program is publicly available from NCBI and other sources. The well
known Smith Waterman algorithm may also be used to determine
identity.
[0081] Preferred parameters for polypeptide sequence comparison
include the following:
[0082] Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453
(1970); Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff,
Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992);
[0083] Gap Penalty: 12; Gap Length Penalty: 4.
[0084] A program useful with these parameters is publicly available
as the "gap" program from Genetics Computer Group, Madison, Wis.
The aforementioned parameters are the default parameters for amino
acid sequence comparisons (along with no penalty for end gaps).
[0085] The polypeptides of the invention may be prepared in any
suitable manner as known in the art. Such polypeptides include
isolated naturally occurring polypeptides, recombinantly produced
polypeptides, synthetically produced polypeptides, or polypeptides
produced by a combination of these methods. Means and methods for
preparing such polypeptides are well known in the art.
[0086] Certain aspects of the invention use UAG polynucleotides.
These include isolated polynucleotides which encode the UAG
polypeptides, fragments and analogs defined in the application. As
used herein, the term "polynucleotide" refers to a molecule
comprised of a plurality of deoxyribonucleotides or nucleoside
subunits. The linkage between the nucleoside subunits can be
provided by phosphates, phosphonates, phosphoramidates,
phosphorothioates, or the like, or by nonphosphate groups as are
known in the art, such as peptoid-type linkages utilized in peptide
nucleic acids (PNAs). The linking groups can be chiral or achiral.
The oligonucleotides or polynucleotides can range in length from 2
nucleoside subunits to hundreds or thousands of nucleoside
subunits. While oligonucleotides are preferably 5 to 100 subunits
in length, and more preferably, 5 to 60 subunits in length, the
length of polynucleotides can be much greater (e.g., up to 100).
The polynucleotide may be any of DNA and RNA. The DNA may be in any
form of genomic DNA, a genomic DNA library, cDNA derived from a
cell or tissue, and synthetic DNA. Moreover, the present invention
may, in certain aspects, use vectors which include bacteriophage,
plasmid, cosmid, or phagemid.
[0087] The expressions "biological activity" or "biological
property", or the term "activity" in reference to the polypeptides
of the present invention, are used interchangeably herein and refer
to the pharmacological, biological or cellular abilities of the
polypeptides of the invention and include, but are not limited to,
the capacity of replacing UAG in the biological functions of UAG as
described in the present application, such as, but not limited to,
modulating AG; inhibiting AG; decreasing circulating AG levels;
decreasing circulating elevated AG levels; decreasing circulating
AG/UAG ratio; decreasing circulating elevated AG/UAG ratio;
ameliorating the symptoms induced by AG levels and/or AG/UAG
levels; facilitating, preventing and/or treating conditions
associated with circulating AG and/or circulating AG/UAG ratio and
facilitating, preventing and/or treating conditions associated with
elevated circulating AG and/or elevated circulating AG/UAG ratio.
[0088] ii) Therapeutic methods, uses and compositions
[0089] According to one embodiment, the modulation of ghrelin
levels and/or modulation of AG/UAG ratio in a subject is desirable
when such modulation is beneficial to the subject. According to
another embodiment, the present invention provides a method for
decreasing AG levels and/or decreasing AG/UAG ratio in a subject.
In some implementations of this embodiment, the subject demonstrate
elevated AG levels and/or an elevated AG/UAG ratio and the symptoms
associated with AG levels and/or associated with AG/UAG ratio are
worsen or exacerbated in this subject.
[0090] In some implementations of these embodiments, the AG levels
refer to the circulating AG levels and the AG/UAG ratio refers to
the circulating AG/UAG ratio. In some further implementations of
this embodiment, the subject shows one or more of the following
symptoms associated with AG levels and/or associated with AG/UAG
ratio: hyperglycemia, insulin resistance, reduced fat utilization,
adiposity, increase food intake, weight gain and suppression of
insulin secretion. In further implementations of this embodiment,
the subject suffers from one or more of the following conditions
associated with the symptoms defined above: diabetes (e.g., type 2
diabetes), Prader-Willi Syndrome (PWS), obesity, obesity associated
with insulin resistance, hyperphagia and hyperghrelinemia. The
method comprises administering an effective amount of UAG,
fragments, analogs, pharmaceutical salts thereof, and/or any
combinations thereof to the subject.
[0091] According to another embodiment, the present invention
provides a method for ameliorating and/or diminishing the symptoms
associated with AG levels and/or associated with AG/UAG ratio in a
subject. In some implementations of this embodiment, the subject
demonstrate elevated AG levels and/or an elevated AG/UAG ratio and
the symptoms associated with AG levels and/or associated with the
AG/UAG ratio are worsen or exacerbated in this subject.
[0092] The present invention thus also provides a method for
ameliorating and/or diminishing the symptoms associated with
elevated AG levels and/or associated with elevated AG/UAG ratio in
such subject.
[0093] The symptoms associated with elevated AG levels include, but
are not limited to, hyperglycemia, insulin resistance, reduced fat
utilization, adiposity, increased food intake, weight gain and
suppression of insulin secretion. The symptoms associated with
elevated AG/UAG ratio include, but are not limited to, insulin
resistance. In some implementations of theses embodiment, the
subject suffers from one or more of the following conditions
associated with the symptoms defined above: diabetes (e.g. type 2
diabetes), Prader-Willi Syndrome (PWS), obesity, obesity associated
with insulin resistance, hyperphagia and hyperghrelinemia. The
method comprises administering an effective amount of UAG,
fragments, analogs, pharmaceutical salts thereof, and/or any
combinations thereof to the subject. In some further
implementations of this embodiment, the AG levels refer to the
circulating AG levels and the AG/UAG ratio refers to the
circulating AG/UAG ratio. The method comprises administering an
effective amount of UAG, fragments, analogs, pharmaceutical salts
thereof and/or any combinations thereof to the subject.
[0094] According to yet another embodiment, the present invention
provides for a method of ameliorating and/or treating a condition,
a disorder or a disease associated with AG levels and/or associated
with AG/UAG ratio. In some implementations of this embodiment, the
AG levels refer to the circulating AG levels and the AG/UAG ratio
refers to the circulating
[0095] AG/UAG ratio. Conditions, disorders or diseases associated
with AG levels include, but are not limited to, diabetes (e.g.,
type 2 diabetes), Prader-Willi Syndrome (PWS), obesity, obesity
associated with insulin resistance, hyperphagia and
hyperghrelinemia. The method comprises administering an effective
amount of UAG, fragments, analogs, pharmaceutical salts thereof
and/or any combination thereof to the subject.
[0096] As used herein, the term "hyperghrelinemia" refers to a
pathological condition caused by elevated circulating AG levels
and/or by an elevated circulating AG/UAG ratio. Subjects suffering
from hyperghrelinemia exhibit symptoms such as, but not limited to,
hyperglycemia, insulin resistance, decreased insulin secretion,
decreased fat utilization, adiposity, weight gain and/or a
combination thereof.
[0097] In some implementations of the present invention, the more
the AG levels are elevated in these subjects, the more pronounced
are the symptoms induced by elevated AG levels and the more
efficient is UAG, fragments, analogs and/or pharmaceutical salts
thereof in ameliorating and/or diminishing these symptoms.
[0098] In some other implementations of the present invention, the
more the AG/UAG ratio is elevated in these subjects, the more
pronounced are the symptoms induced by an elevated AG/UAG ratio and
the more efficient is UAG, fragments, analogs and/or pharmaceutical
salts thereof in ameliorating and/or diminishing these
symptoms.
[0099] According to yet another embodiment, the present invention
provides for a method for counteracting the peripheral actions of
AG as well as to decrease AG levels and to ameliorate the symptoms
induced by AG levels.
[0100] To the extent that new and yet uncovered conditions,
diseases and disorders can be ameliorated, prevented and/or treated
with the reduction in AG and/or a reduction in AG/UAG ratio, the
methods of the present invention can be utilized with respect to
those conditions, disorders and diseases.
[0101] In one implementation of these embodiments, the method
includes the step of administering an effective amount of UAG or of
a polypeptide defined herein which shares the same potential
therapeutic indication as UAG itself to the subject in need of such
administration.
[0102] Such polypeptide comprises the amino acid sequence set forth
in SEQ ID NO: 1, or comprises any fragment or any analog thereof
such as for example, those described in the above tables.
[0103] The actions of UAG have previously been shown to be
conserved by fragments UAG (6-13) (SEQ ID NO: 6), UAG (8-13) (SEQ
ID NO: 7), UAG (8-12) (SEQ ID NO: 8), UAG (8-11) (SEQ ID NO: 12),
UAG (9-12) (SEQ ID NO: 11) and UAG (9-11) (SEQ ID NO: 29). U.S.
Pat. Nos. 8,222,217 and 8,318,664, incorporated herein in their
entirety, have shown that these fragments retain the activity of
UAG full length on glucose, insulin and lipid metabolisms. A
peptide with the inverse sequence of UAG (1-14) (SEQ ID NO: 3) and
named UAG (14-1) (SEQ IDNO: 30) was used as a negative control in
the experiments testing UAG fragments. UAG (8-11) (SEQ ID NO: 10)
was shown to be the smallest UAG fragment to retain UAG activities.
The results provided herein further indicate that UAG fragments,
such as for example, UAG (6-13) (SEQ ID NO: 6) and cyclic UAG
(6-13) (SEQ ID NO: 25) retain UAG's ability to decrease AG levels
and decrease AG/UAG ratio.
[0104] In a further embodiment, UAG, fragments and/or analogs
thereof are used to reduce the elevated AG levels associated with
Prader-Willi Syndrome (PWS). People who suffer from PWS suffer from
slowed development, severe obesity and an insatiable appetite.
Their hunger is so strong that it often requires custodial
enforcement of food availability to avert early death as a result
of hyperphagia. AG concentrations in these subjects are higher than
normal. This correlation between hyperphagia and increase AG levels
is consistent with the known orexigenic effect of AG. The data
present herein demonstrate that administration of UAG can decrease
the elevated AG levels in PWS subjects. The methods of the
invention can be used to help patients with Prader-Willi syndrome
reduce their ghrelin levels to more normal/healthier levels, curb
their appetite, and/or ameliorate other manifestations of this
disorder. This decrease in AG is expected to translate into a
decrease in appetite and in a subsequent reduction in fat mass
associated with PWS.
[0105] As used herein, the term "hyperphagia" refers to excessive
hunger and abnormally large intake of solids by mouth. Hyperphagic
conditions may occur in association with for example, central
nervous system (CNS) disorders including gangliocytoma of the third
ventricle, hypothalmic astrocytoma, Kleine-Levin Syndrome,
Froehlich's Syndrome, Parkinson's Disease, genetic disorders
including Praeder-Willi Syndrome, major psychiatric disorders
including anxiety, major depressive disorder, depressive phase of
bipolar disorder, seasonal affective disorder, and schizophrenia,
psychotropic medication, including delta-9 tetrahydrocannabinol,
antidepressants and neuroleptics and sleep disorders including
sleep apnea. Hyperphagia may occur in psychiatric disorders such as
depression, anxiety and schizophrenia. In some embodiments,
administration of UAG, fragments and/or analogs thereof may reduces
the hyperphagia associated with these conditions.
[0106] As used herein, the term "treatment" refers to both
therapeutic treatments as well as to prophylactic measures. Those
in need of treatment include those already with the disorder,
disease or condition as well as those in which the disease,
disorder or condition is to be prevented. Those in need of
treatment are also those in which the disorder, disease or
condition has occurred and left after-effects or scars. Treatment
also refers to administering a therapeutic substance effective to
improve or ameliorate, diminish symptoms associated with a disease,
a disorder or a condition to lessen the severity of or cure the
disease, disorder or condition, or to prevent the disease, disorder
or condition from occurring or reoccurring.
[0107] Studies have demonstrated a persistent increase in plasma AG
levels up to one year following a diet-induced weight loss in obese
subjects (Refs. 28 and 29). The reduction of elevated AG levels in
these subjects could thus prevent obesity relapse while the subject
is under diet. Therefore, in yet a further embodiment, the present
invention provides a method for improving the efficacy of
diet-induced weight loss and/or for preventing weight gain
following diet-induced weight loss in a subject in need of weight
loss or in need of maintaining a weight loss by administering an
effective amount of UAG, fragments, analogs and/or pharmaceutical
salts thereof to the subject.
[0108] In a further implementation of this embodiment, UAG,
fragments and/or analogs thereof are administered at the onset of
the diet program and preferably, UAG, fragments and/or analogs
thereof are also administered throughout the diet program.
[0109] It is a further aspect of the present invention to provide
for any pharmaceutical composition incorporating at least one of
the polypeptides as defined herein.
[0110] For therapeutic and/or pharmaceutical uses, the polypeptides
as defined herein may be formulated for, but not limited to,
intravenous, subcutaneous, transdermal, topical, oral, buccal,
sublingual, nasal, inhalation, pulmonary, or parenteral
administration according to conventional methods. Intravenous
injection may be by bolus or infusion over a conventional period of
time. The polypeptides as defined herein may also be administered
directly to a target site within a subject e.g., by biolistic
delivery to an internal or external target site or by catheter to a
site in an artery.
[0111] In one embodiment, the polypeptides defined herein are
administered as a bolus. Accordingly, in one implementation of this
embodiment, the medicament is administered as a bolus prior to
meal, wherein the bolus comprises an effective amount of UAG, a
fragment and/or an analog thereof of a salt thereof. The bolus may
be administered one, twice, three times or more daily or may be
administered according to other dosage regimens.
[0112] Suitable dosage regiments are determined taking into account
factors well known in the art such as, but not limited to, type of
subject being dosed, the age, the weight, the sex and the medical
condition of the subject, the route of administration, the desired
affect, etc.
[0113] Active ingredients, such as the polypeptides defined herein,
may be administered orally as a suspension and can be prepared
according to techniques well known in the art of pharmaceutical
formulation and may contain, but not be limited to,
microcrystalline cellulose for imparting bulk, alginic acid or
sodium alginate as a suspending agent, methylcellulose as a
viscosity enhancer, and sweeteners/flavoring agents. As immediate
release tablets, these compositions may contain, but are not
limited to microcrystalline cellulose, dicalcium phosphate, starch,
magnesium stearate and lactose and/or other excipients, binders,
extenders, disintegrants, diluents and lubricants. The active
ingredients may be administered by way of a controlled-release
delivery system.
[0114] Administered by nasal aerosol or inhalation formulations may
be prepared, for example, as solutions in saline, employing benzyl
alcohol or other suitable preservatives, absorption promoters to
enhance bioavailability, employing fluorocarbons, and/or employing
other solubilizing or dispersing agents.
[0115] The polypeptides of the invention may be administered in
intravenous (both bolus and infusion), intraperitoneal,
subcutaneous, topical with or without occlusion, or intramuscular
form. When administered by injection, the injectable solution or
suspension may be formulated using suitable non-toxic,
parenteral-acceptable diluents or solvents, well known in the
art.
[0116] The polypeptides of the invention may also be formulated for
topical administration. The term "topical" as used herein includes
any route of administration that enables the compounds to line the
skin or mucosal tissues.
[0117] The formulation suitable for topical application may be in
the form of, for example, cream, lotion, solution, gel, ointment,
paste, plaster, paint, bioadhesive, or the like, and/or may be
prepared so as to contain liposomes, micelles, microparticles
and/or microspheres. The formulation may be aqueous, i.e., contain
water, or may be non-aqueous and optionally used in combination
with an occlusive overlayer so that moisture evaporating from the
body surface is maintained within the formulation upon application
to the body surface and thereafter.
[0118] Ointments, as is well known in the art of pharmaceutical
formulation, are semisolid preparations that are typically based on
petrolatum or other petroleum derivatives. Formulations may also be
prepared with liposomes, micelles, microparticles and/or
microspheres. Liposomes are microscopic vesicles having a lipid
wall comprising a lipid bilayer, and can be used as drug delivery
systems. Micelles are known in the art to be comprised of
surfactant molecules arranged so that their polar head groups form
an outer spherical shell, while the hydrophobic, hydrocarbon chains
are oriented towards the center of the sphere, forming a core.
Microparticles are particulate carrier systems in the micron size
range, normally prepared with polymers, which can be used as
delivery systems for drugs or vaccines that are usually trapped
within the particles. Microspheres, similarly, may be incorporated
into the present formulations and drug delivery systems. Like
liposomes and micelles, microspheres essentially encapsulate a drug
or drug-containing formulation. Microspheres are generally,
although not necessarily, formed from synthetic or naturally
occurring biocompatible polymers, but may also be comprised of
charged lipids such as phospholipids.
[0119] Preparations of formulations suitable for topical
administration are well known in the art and described in the
pertinent texts and literature.
[0120] In general, pharmaceutical compositions will comprise at
least one of the polypeptides of the invention together with a
pharmaceutically acceptable carrier which will be well known to
those skilled in the art. The compositions may further comprise for
example, one or more suitable excipients, diluents, fillers,
solubilizers, preservatives, carriers, salts, buffering agents and
other materials well known in the art depending upon the dosage
form utilized.
[0121] Methods of composition are well known in the art.
[0122] In the present context, the term "pharmaceutically
acceptable carrier" is intended to denote any material, which is
inert in the sense that it substantially does not have any
therapeutic and/or prophylactic effect per se and that are
non-toxic. A pharmaceutically acceptable carrier may be added to
the polypeptides of the invention with the purpose of making it
possible to obtain a pharmaceutical composition, which has
acceptable technical properties.
[0123] Examples of such carriers include ion exchangers, alumina,
aluminum stearate, lecithin, serum proteins, such as human serum
albumin, buffer substances such as phosphates, glycine, sorbic
acid, potassium sorbate, partial glyceride mixtures of saturated
vegetable fatty acids, water, salts, or electrolytes such as
protamine sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and
PEG.
[0124] Carriers for topical or gel-based forms of polypeptides
include polysaccharides such as sodium carboxymethylcellulose or
methylcellulose, polyvinylpyrrolidone, polyacrylates,
polyoxyethylene-polyoxypropylene-block polymers, PEG, and wood wax
alcohols.
[0125] The polypeptides used for in vivo administration must be
sterile. This may be accomplished by filtration through sterile
filtration membranes, prior to or following lyophilization and
reconstitution. The polypeptides ordinarily will be stored in
lyophilized form or in solution.
[0126] Therapeutic polypeptide compositions generally are placed
into a container having a sterile access port, for example, an
intravenous solution bag or vial having a stopper pierceable by a
hypodermic injection needle.
[0127] For use in the methods defined herein, the invention also
provides an article of manufacture or a commercial package or kit,
comprising: a container, a label on the container, and a
composition comprising the polypeptides of the invention as an
active agent within the container when used at the indicated level,
wherein the composition is effective for, inter alia, modulating
AG; inhibiting AG; decreasing circulating AG levels; decreasing
circulating elevated AG levels; decreasing circulating AG/UAG
ratio; decreasing circulating elevated AG/UAG ratio; ameliorating
the symptoms induced by AG levels and/or AG/UAG levels;
facilitating, preventing and/or treating conditions associated with
circulating AG and/or circulating AG/UAG ratio and/or facilitating,
preventing and/or treating conditions associated with elevated
circulating AG and/or elevated circulating AG/UAG ratio.
[0128] An "effective amount" or a "therapeutically effective
amount" refers to an amount effective, at dosages and for periods
of time necessary, to achieve the desired therapeutic result. A
therapeutically effective amount of the peptides noted herein may
vary according to factors such as the disease state, age, sex, and
weight of the individual, and the ability of the compound to elicit
a desired response in the individual. Dosage regimens may be
adjusted to provide the optimum therapeutic response. A
therapeutically effective amount is also one in which any toxic or
detrimental effects of the compound are outweighed by the
therapeutically beneficial effects. A "prophylactically effective
amount" refers to an amount effective, at dosages and for periods
of time necessary, to achieve the desired prophylactic result, such
as to modulate AG; inhibit AG; decrease circulating AG levels;
decrease circulating elevated AG levels; decrease circulating
AG/UAG ratio; decrease circulating elevated AG/UAG ratio;
ameliorate the symptoms induced by AG levels and/or AG/UAG levels;
facilitate, prevent and/or treat conditions associated with
circulating AG and/or circulating AG/UAG ratio and/or facilitate,
prevent and/or treat conditions associated with elevated
circulating AG and/or elevated circulating AG/UAG ratio. A
prophylactically effective amount can be determined as described
above for the therapeutically effective amount. For any particular
subject, specific dosage regimens may be adjusted over time
according to the individual need and the professional judgment of
the person administering or supervising the administration of the
compositions.
[0129] For example, a therapeutically effective amount or effective
dose of the peptides of the invention (also referred to herein as
"active compound") is an amount sufficient to modulate AG; inhibit
AG; decrease circulating AG levels; decrease circulating elevated
AG levels; decrease circulating AG/UAG ratio; decrease circulating
elevated AG/UAG ratio; ameliorate the symptoms induced by AG levels
and/or AG/UAG levels; facilitate, prevent and/or treat conditions
associated with circulating AG and/or circulating AG/UAG ratio
and/or facilitate, prevent and/or treat conditions associated with
elevated circulating AG and/or elevated circulating AG/UAG ratio.
The methods and/or assays for measuring such parameters are known
to those of ordinary skill in the art.
[0130] The therapeutically effective amount of the invention will
generally vary from about 0.001 .mu.g/kg to about 10 mg/kg, more
particularly from about 0.01 .mu.g/kg to about 10 mg/kg, and even
more particularly from about 1 .mu.g/kg to about 1 mg/kg.
Therapeutically effective amounts or effective doses that are
outside this range but that have the desired therapeutic effect are
also encompassed by the present invention.
[0131] In a one embodiment, the subject noted above is a mammal, in
a further aspect, a human.
[0132] In a further embodiment, the present polypeptides may be
administered in combination with additional pharmacologically
active substances or may be administered in combination with
another therapeutic method. The combination may be in the form of a
kit-in-part system, wherein the combined active substances may be
used for simultaneous, sequential or separate administration.
[0133] iii) AG levels and AG/UAG ratio as biomarkers
[0134] According to another embodiment, the present invention
relates to the use of circulating AG levels and the use of
circulating AG/UAG ratio as biomarkers for the identification of
subjects that are likely to respond to and/or benefit from a
treatment comprising the administration of a therapeutically
effective amount of UAG, a fragment thereof and/or an analog
thereof.
[0135] In one implementation of this embodiment, circulating AG
levels and/or circulating AG/UAG ratio are measured in a blood
sample obtained from a subject according to known methods in the
art. The level of circulating AG and/or the ratio of circulating
AG/UAG are then processed in part based on reference circulating
levels of AG and reference circulating AG/UAG ratios (derived, for
example, from the subject himself or from a population of control
subjects) so as to derive information which conveys whether the
subject has an abnormal level of circulating AG (i.e., below or
above a normal or healthy level) and/or an abnormal ratio of
circulating AG/UAG (i.e., below or above a normal or healthy
ratio). An information which conveys that the subject has an
elevated circulating AG level and/or an elevated circulating AG/UAG
ratio indicates that the subject is likely to respond to
administration of UAG, a fragment thereof or an analog thereof.
Administration of UAG, a fragment thereof or an analog thereof in
such subject is thus likely to decrease circulating AG levels
and/or circulating AG/UAG ratio as well as to lessen the effects
associated with elevated circulating AG levels and elevated
circulating AG/UAG ratio.
[0136] In another implementation of this embodiment, the subject
suffers from a condition such as, but not limited to, diabetes
(type 1 or type 2), obesity, Prader-Willy, insulin resistance,
hyperphagia and hyperghrelinemia. The biomarkers defined herein may
be used to determine if such subject is likely to response and/or
is likely to benefit from administration of UAG, a fragment thereof
or an analog thereof. A subject suffering from such a condition and
having an elevated circulating AG level and/or an elevated
circulating AG/UAG ratio is likely to respond and/or benefit from
administration of UAG, a fragment thereof and/or an analog
thereof.
[0137] In another implementation of this embodiment, the biomarkers
may be used for identifying subjects within a population of
subjects that are likely to respond to and/or benefit from
administration of a therapeutically effective amount of UAG, a
fragment thereof or an analog thereof. In this implementation, the
subjects of the population suffer from a condition such as, but not
limited to, diabetes (type I or type 2), Prader-Willi Syndrome
(PWS), obesity, insulin resistance, hyperphagia and
hyperghrelinemia.
[0138] In accordance with another implementation of this
embodiment, the present invention provides a method of displaying
information conveying a subject's likelihood of responding to
and/or benefiting from administration of UAG, a fragment thereof
and/or an analog thereof.
[0139] Such implementation may, for example, by carried out by an
apparatus, such as, but not limited to, a computer readable storage
medium storing a program element suitable for execution by a
computer unit. In such implementation, the program element
implements a graphical user interface module which displays
information conveying the subject's likelihood of responding to
and/or benefiting from administration of UAG, a fragment thereof
and/or an analog thereof.
[0140] The graphical user interface module is adapted for
displaying a set of user modifiable information fields allowing a
user to enter a set of information data elements associated to the
subject's level of circulating AG, level of circulating UAG and/or
circulating AG/UAG ratio measured according to methods known in the
art. The graphical user interface module is also adapted for
displaying a control allowing a user to cause the set of
information data elements to be transmitted to a processing unit.
The processing unit is adapted to derive a subject's likelihood of
responding to and/or benefiting from administration of UAG, a
fragment thereof and/or an analog thereof at least in part on the
basis of the set of information data elements. The graphical user
interface module receives the subject's level of circulating AG,
level of circulating UAG and/or circulating AG/UAG ratio and is
adapted to display the subject's likelihood of responding to and/or
benefiting from administration of UAG, a fragment thereof and/or an
analog thereof with reference to normal or healthy circulating AG
levels and/or normal or healthy circulating AG/UAG ratio (derived,
for example, from the subject or from a population of control
subjects). Optionally, the graphical user interface module is
adapted to display the subject's likelihood of responding to and/or
benefiting from administration of UAG, a fragment thereof and/or an
analog thereof with reference to circulating AG levels and/or
circulating AG/UAG ratio observed in subjects suffering from a
condition such as, but not limited to, diabetes (type I or type 2),
Prader-Willi Syndrome (PWS), obesity, insulin resistance,
hyperphagia and hyperghrelinemia In accordance with a specific
implementation, the set of information data elements may also
comprise a gender component, a weight component, a body mass index
(BMI) component, a fitness component. The set of information data
elements may further include any other suitable item of information
associated with the subject.
[0141] In accordance with a specific implementation, the subject's
likelihood of responding to and/or benefiting from administration
of UAG, a fragment thereof and/or an analog thereof includes an
indicative data element conveying a likelihood of responding to
and/or benefiting from administration of UAG, a fragment thereof
and/or an analog thereof. The indicative data element may be
expressed in the form of a score, likelihood, a percentile value or
in any other format suitable.
[0142] In accordance with a specific implementation, the graphical
user interface module is adapted for displaying a graph conveying
the likelihood of a subject to respond to and/or to benefit from
administration of AUG, a fragment thereof and/or an analog thereof,
the graph conveying: a first information indicative of a reference
normal/healthy level of circulating AG and/or a reference
normal/healthy circulating AG/UAG ratio (optionally, the graphical
user interface module is adapted for displaying information
indicative of reference circulating AG levels and circulating
AG/UAG ratios in subjects suffering from a condition such as, but
not limited to, diabetes (type I or type 2), Prader-Willi Syndrome
(PWS), obesity, insulin resistance, hyperphagia and
hyperghrelinemia); a second information indicative of the subject's
circulating level of AG, circulating level of UAG and/or
circulating AG/UAG ratio; and a third information conveying a
likelihood of the subject to respond to and/or to benefit from UAG
administration
[0143] Experiments and Data Analysis
[0144] The data present herein reports a strong suppressing effect
of UAG on serum AG levels and on serum AG/UAG ratio in T2DM
subjects.
[0145] A continuous overnight (15 hours) infusion of two doses of
UAG (3 .mu.g UAG/kg/hr and 10 .mu.g UAG/kg/hr) versus placebo in a
cross-over model on the AG concentrations was performed in eight
overweight subjects with type 2 diabetes. FIG. 1 depicts a
schematic representation of the study protocol. Glucose and insulin
responses to a standard breakfast meal (SBM) in the subjects and
reasonable metabolic control were assessed. During the infusions
with UAG, subjects did not report more side effects than placebo.
Laboratory evaluations showed no significant changes in chemistry
or parameters and the side effects were not dose-dependent.
[0146] Infusion of UAG Decreases Plasma AG Levels
[0147] The data present in FIGS. 2A and 2B show the changes in
serum AG levels (FIG. 2A) and UAG levels (FIG. 2B) before and after
SBM. Before initiation of SBM, AG levels are significantly
decreased from 21.01.+-.8.9 pg/ml (mean.+-.SD) during placebo
infusion to 3.0.+-.6.7 pg/ml in the presence 3 mcg/kghr UAG
infusion and to 1.4.+-.3.2 pg/ml in the presence of 10 mcg/kghr UAG
infusion. AG levels are also decreased following SMB from
14.03.+-.9.4 pg/ml in placebo to 0.8.+-.1.8 pg/ml in the presence 3
mcg/kghr UAG infusion and to 0.8.+-.1.8 pg/ml in the presence of 10
mcg/kghr UAG infusion (FIG. 2A). In parallel, an overnight infusion
of UAG resulted in an increase in UAG levels (FIG. 2B). UAG levels
increased from 105.9.+-.31.4 (mean.+-.SD) pg/ml in placebo infusion
and before start of the SBM to 10998.+-.2623 pg/ml in the presence
3 mcg/kghr UAG infusion and to 12085.+-.1616 pg/ml in the presence
of 10 mcg/kghr UAG infusion. These results indicate that
administration of UAG reduces serum AG levels in T2DM subjects.
[0148] Infusion of UAG Fragment Counteracts AG-Induced Food
Intake
[0149] A cyclized fragment of UAG, namely cyclic UAG (6-13) as
depicted in SEQ ID NO: 25, was able to counteract the orexigenic
effects induced by AG in rat (FIG. 8). These results demonstrate
that UAG fragments as defined herein which retain the core sequence
responsible for UAG-related actions/activities also retain their
effects on AG levels. As discussed above, there is a benefit of
inhibiting the effect of AG or its levels (e.g. devcreasing food
consumption) in certain subjects. These results demonstrate a
beneficial role for UAG in the treatment of patients with Prader
Willi syndrome, in whom elevated AG levels are associated with
hyperphagia. Inhibition of AG levels and/or biological effects
should thus result in decreased appetite and/or food
consumption.
[0150] Infusion of UAG Decreases Post-Prandial Plasma Glucose
Levels
[0151] An overnight infusion of UAG significantly depressed
post-prandial glucose levels as assessed by iPro continuous glucose
monitoring (FIGS. 3A and 3B). The area under the curves decreased
from 1618 mmol/3 hrs for placebo infusion to 1601 mmol/3 hrs and
1540 mmol/3 hrs for the 3 and 10 mcg UAG infusions respectively.
FIGS. 4A and 4B depict the results obtained as changes from the
glucose pre-SBM baseline. The area under the curves decreased for
the 3 and 10 mcg UAG infusions doses when compared to placebo.
FIGS. 5A and 5B indicate a decrease in plasma glucose peak after
SBM when UAG is administered. An overall decrease in post-prandial
plasma glucose peaks can be observed in the subjects (FIG. 5B).
Overall, these data indicate that administration of UAG decreases
post-prandial plasma glucose levels in subjects with T2DM.
[0152] UAG-Induced Reduction in Plasma AG Levels and AG/UAG Ratio
Correlates with Reduction in Glucose Levels
[0153] The inventors were able to show the existence of a
correlation between fasting AG levels and/or UAG levels and
glycemic response following UAG administration using a standard
glucokinase assay. Further to demonstrating such correlation, FIG.
6A shows that the more elevated the fasting AG levels are, the best
are the hypoglycemic effect of UAG administration. FIG. 6B also
shows the same correlation and effect using iPro continuous glucose
measurements. Fasting AG/UAG ratio also correlates with the
glycemic response following UAG administration (FIG. 6C). The
higher AG/AUG ratios correlate with the best hypoglycemic effect of
UAG infusion using iPro continuous glucose measurements.
[0154] Infusion of UAG Improves Insulin Sensitivity
[0155] Insulin sensitivity in T2DM subjects was assessed using the
hyperinsulinemic-euglycemic clamp protocol as depicted in FIG. 7A.
In patients receiving effective euglycemic insulin clamp at the
start of a 2.5 hr placebo/UAG infusion, the M-index change from
baseline was increased by 36% in the UAG vs. placebo group (p=0.02)
(FIG. 7B). These results demonstrate that UAG infusion improves
insulin resistance in T2DM subjects.
[0156] Shorter UAG Infusion is Sufficient to Decrease Plasma AG
Levels
[0157] AG levels were measured in T2DM subjects prior to UAG
infusion and following a 2.5 hour-long UAG infusion. The data
presented in FIG. 7C shows that the shortened UAG infusion period
was sufficient to decrease plasma AG levels. FIG. 7D indicates the
changes in AG levels from baseline demonstrating that a short UAG
infusion period suffices to decrease plasma AG levels.
[0158] These data demonstrate, inter alia, that administration of
UAG improves glucose levels during a SBM through a reduction in AG.
A significant decrease in peak glucose levels after meal was also
observed. No significant change in serum insulin levels during the
infusion of low and high dose of UAG infusions was observed (data
not shown), which indicates that the improved glycemic control
correlates with an improved insulin sensitivity. The data also show
that administration of UAG improves hyperglycemia in a ghrelin
concentration dependent manner thus making the UAG hypoglycemic
effects stronger at higher AG levels or at higher AG/UAG ratio.
[0159] These results are the first indication that UAG is a potent
inhibitor of ghrelin levels making UAG a strong candidate for the
development of a ghrelin inhibitor in the treatment of metabolic
disorders.
[0160] Materials and Technical Protocols
[0161] Study design--Single-center, investigator initiated, double
blind and placebo controlled randomized study. During the first
visit medical history, medication use and vital signs of subjects
were checked. Blood samples were also taken for chemistry and
hematology analysis. The study consisted of three rounds of
hospitalization (visit 2, 3 and 4) of two days each.
[0162] The first day started at approximately 15:00 and continued
until 14:00 the next day. The eight subjects were divided into 3
groups for the study. The dosages used during these rounds were
either 3 mcg/kghr UAG, 10 mcg/kghr UAG or placebo/saline solution
prepared by the hospital pharmacy and delivered in 3 bags for each
subject. Neither subjects nor researchers were aware of the drug
given in these rounds. A washout period of one week was performed
between the treatment periods.
[0163] Before, during and after the study, blood samples were taken
for, AG, UAG, chemistry, hematology and CAC cells. Blood samples
for glucose were also taken via i.v catheter. For continuous
glucose monitoring a Continuous Glucose monitor (iPro2, Medtronic
trading, The Netherlands) was placed in the abdomen of the
subjects. Weight and blood pressure were measured during each
visit. A washout period of at least 1 week was performed between
the treatment periods.
[0164] Subjects--Eight subjects were enrolled (2 females and 6
males; mean age of 53 yrs (ranging from 31-65 years old) with mean
body mass index (BMI) of 31.5 kg/m.sup.2, range 26-36 kg/m.sup.2.
Seven of the eight subjects used metformin daily. All subjects were
diagnosed with type 2 diabetes for at least 3 months prior to
enrollment. Metformin monotherapy for at least 3 months prior to
screening was allowed, but metformin treatment was stopped 1 day
prior to start of each treatment period. In the population mean
glycosylated hemoglobin level (HbA1c) was 52 mmol/mol range from 48
mmol/mol to 57 mmol/mol (6.9%; range 6.5-7.4%).) and Body Mass
Index was above 25 kg/m.sup.2. Exclusion criteria consisted in
history or presence of long-term type 2 diabetes complications;
clinically significant abnormalities in laboratory evaluation at
screening, and use of systemic corticosteroids within 60 days prior
to screening. Prior to infusion, subjects received two indwelling
catheters: the first catheter was inserted prior to treatment; and
the second catheter was inserted prior to the SBM for blood
sampling. The second catheter was kept patent by slow infusion of
isotonic saline.
[0165] Study drug--UAG used in this study was produced by Bachem
AG, Hauptstrasse 144, Bubendorf CH-4416, Switzerland. UAG was
delivered as lyophilized powder (vials containing 5 mg of drug) and
stored at the local pharmacy according to the manufacturer's
specifications.
[0166] Study procedures--Infusions were performed at the local
clinical research unit for 15 hours from 9 pm to 12 am. Each volume
of UAG solution was filtered and diluted in 0.9% of saline solution
to obtain the appropriate dose for administration. Placebo
consisted in 0.9% of saline solution. The dose was calculated based
on the subject's weight. Each vial was reconstituted with 5 ml
water for injection, filtered through a 0.22 .mu.m filter. The dose
was then injected in a 500 ml bag of 0.9% NaCl. Three bags were
prepared to ensure a continuous 15-hour infusion at 100
ml/hour.
[0167] Standard breakfast meal (SBM) consisted of: [0168] 3 slices
wheat bread; p1 3 portions of margarine; [0169] 2 slices of cheese
(48% fat); [0170] 1 portion of jam; [0171] 1 cup of whole milk; and
[0172] 1 boiled egg; for a total of 714 kcal (17% proteins; 46%
fat; and 37% carbohydrates). The SBM had to be consumed within 15
minutes, from 8:00 am to 8:15 am. At each of the 3 visits, the
following safety parameters were assessed: hemoglobin, hematocrit,
platelet count, WBC count, RBC count, and differential and were
determined using Sysmex XE 2100, Firma Sysmex, Ecustraat 11, 4879
NP Etten-Leur. AST, ALT, alkaline phosphatase, total bilirubin,
creatine phophokinase (CPK), lactate dehydrogenase (LDH),
creatinine, urea, amylase, lipase, uric acid, glucose, cholesterol,
LDL, HDL, triglycerides, sodium, potassium, calcium, chloride,
protein and albumin are determined using the Hitachi Modular P800,
Roche Transistorstraat 41, 1332 CK Almere. Blood glucose levels
were measured using a continuous glucose monitoring device
(Medtronic CGMS iPro.TM. Continuous Glucose Recorder, Medtronic;
The Netherlands) that was subcutaneously inserted for the whole
treatment period. Serum glucose levels (using the in-house
glucokinase assay) were also assessed every 30 minutes and starting
before, and continuing for 4 hours after, the SBM. During the CGMS,
all subjects had to perform at least four capillary glycemic tests
per day. The data collected were entered into the CGMS monitor to
obtain correlation coefficients between the SMBG and the CGMS
values. All SMBG tests were performed using a digital glucometer
(Contour, Bayer). AG and UAG levels were assessed before the start
of the overnight infusion, 10 minutes before the start and 30
minutes after the SBM. To preserve acylation of ghrelin, blood
samples were collected directly into EDTA tubes, then within 2
minutes 1 ml of EDTA-blood was added to 1 ml of preservative
solution on ice (0.0295 N HCl containing 72 mM NaCl, 58 mM NaF, 4
mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (a water
soluble, irreversible serine protease inhibitor; AEBSF), pH 3.0,
295 mOsm/KgPlasma was prepared by centrifugation at 4.degree. C.,
then 1 ml was acidified with 100 .mu.l 1N HCl and stored at
-80.degree. C. until assays were performed.
[0173] The ghrelin assay utilized MSD ELISA 96-well plates (Meso
Scale Discovery (MSD), Gaithersburg, MD, USA) coated by incubation
with 30 .mu.l/well of capture antibody (D4 diluted to 1 .mu.g/ml in
PBS; anti-C-terminal ghrelin (Gutierrez et al. 2008 PNAS
105:6320-6325)), overnight at room temperature. The capture
antibody was removed and wells were blocked with 150 .mu.l casein
buffer (Pierce) for 1 h at room temperature with shaking. Standards
for
[0174] AG and UAG were prepared using eight 4.times. serial
dilutions in casein buffer starting at 8 ng/ml and 30 ng/ml,
respectively. Preserved plasma was diluted 1:1 in casein buffer.
Separate plates were used for detection of AG and UAG. Standards
and samples (25 .mu.l/well) were loaded onto coated ELISA plates,
and incubated at room temperature with shaking for 2 hours, washed
3.times. with PBS-T (150 .mu.l/well). The C2-4a1 and E8 detection
antibodies (N-terminal AG and N-terminal UAG, respectively) were
sulfotagged using the standard protocol from MSD. They were then
diluted 1:10000 in 0.2.times. casein/0.05% Tween 20 and added to AG
or UAG plates, respectively, at 25 .mu.l/well. Plates were
incubated at room temperature for 1 hour with shaking. Plates were
washed three times with PBS-T (150 .mu.l/well). Finally, 150 .mu.l
of 1.times. Read Buffer (MSD) was added to each well, and the
plates were immediately read on an MSD Sector Imager 6000. AG and
UAG values for samples were calculated by interpolation from their
respective standard curves using Sector Imager software.
[0175] Clamp study--Randomized 2-period, 2-treatment, double-blind
study of UAG vs. vehicle infusion, evaluating one dose (10
.mu.g/kg/h) of UAG administrated by continuous iv infusion for 2.5
hrs. In patients receiving effective euglycemic insulin clamp at
the start of a 2.5 hr placebo/UAG infusion.
[0176] Statistical analyses--Data analyses were performed with the
GraphPad Prism 5.0 (GraphPad Software, Inc. La Jolla, Calif. 92037
USA). The results are given as means (.+-.SE). Comparisons were
calculated using Bonferroni's Multiple Comparisons, Wilcoxon
matched-pairs signed-rank tests and ANOVA analyses.
[0177] With respect to the experimental data presented in FIG. 8,
Sprague-Dawley rats of 7 weeks of age, weighing between 275 g and
300 g, were fed a pellet diet ad libitum and were singly housed in
plastic cage. The experiment was performed at 2.5 h after the onset
of the light cycle in freely fed rats. The rates were i.p. injected
simultaneously with vehicle plus vehicle, vehicle+AG (13 .mu.g/kg)
or cyclised UAG (6-13) (SEQ ID NO: 25) (42 .mu.g/kg)+AG (13
.mu.g/kg). Immediately after the completion of the i.p. injection
in rats, the night-ad-libitum food was removed and replaced by 2
pellets for each animal, previously weighed, placed into the top of
the cage. Food intake was calculated as the difference between the
food weight before and after the feeding period at each time
interval (30 min, 1 h, and 2 h). Cumulative food intake was
calculated by summating the values of the different time
periods.
[0178] While the invention has been described in connection with
specific embodiments thereof, it will be understood that it is
capable of further modifications and this application is intended
to cover any variations, uses, or adaptations of the invention
following, in general, the principles of the invention and
including such departures from the present disclosure as come
within known or customary practice within the art to which the
invention pertains and as may be applied to the essential features
hereinbefore set forth, and as follows in the scope of the appended
claims.
[0179] All documents mentioned in the specification are herein
incorporated by reference.
REFERENCE LIST
[0180] 1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H and.
Kangawa K; Ghrelin is a growth-hormone-releasing acylated peptide
from stomach, Nature 402:656-660 (1999). [0181] 2. Gnanapavan S,
Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya
S, Carpenter R, Grossman A B and Korbonits M; The tissue
distribution of the mRNA of ghrelin and subtypes of its receptor,
GHS-R, in humans, J. Clin. Endocrinol. Metab. 87:2988-2991 (2002).
[0182] 3. Howard A D, Feighner S D, Cully D F, Arena J P, Liberator
P L, Rosenblum C I, Hamelin M, Hreniuk D L, Palyha O C, Anderson J,
Paress P S, Diaz C, Chou M, Liu K K, McKee K-K, Pong S-S, Chaung
L-Y, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji
D, Dean D C, Melillo D G, Patchett A A, Nargund R, Griffin P R,
DeMartino J A, Gupta S K, Schaeffer J A, Smith R G, Van der Ploeg L
H T; A receptor in pituitary and hypothalamus that functions in
growth hormone release. Science 273:974-977 (1996). [0183] 4.
Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda
M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi
K, Hosoda H, Kojima M, Kangawa K, Nakao K.; Stomach is a major
source of circulating ghrelin, and feeding state determines plasma
ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol
Metab. October; 86(10):4753-8 (2001) [0184] 5. Date Y, Murakami N,
Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato
M. The role of the gastric afferent vagal nerve in ghrelin-induced
feeding and growth hormone secretion in rats. Gastroenterology
123(4):1120-1128, 2002. [0185] 6. Kojima M, Hosoda H, Date Y,
Nakazato M, Matsuo H, Kangawa K. Ghrelin is a
growth-hormone-releasing acylated peptide from stomach. Nature
402(6762):656-660, 1999. [0186] 7. Tschop M, Smiley D L, Heiman M
L. Ghrelin induces adiposity in rodents. Nature 407(6806):908-913,
2000. [0187] 8. Broglio F, Gianotti L, Destefanis S, Fassino S,
Abbate Daga G, Mondelli V, Lanfranco F, Gottero C, Gauna C, Hofland
L, Van Der Lely A J, Ghigo E. The endocrine response to acute
ghrelin administration is blunted in patients with anorexia
nervosa, a ghrelin hypersecretory state. Clin Endocrinol (Oxf)
60(5):592-599, 2004. [0188] 9. Tong J, Prigeon R L, Davis H W,
Bidlingmaier M, Kahn S E, Cummings D E, Tschop MH, D'Alessio D.
Ghrelin suppresses glucose-stimulated insulin secretion and
deteriorates glucose tolerance in healthy humans. Diabetes Sep;
59(9):2145-51 (2010). [0189] 10. Cummings D E, Clement K, Purnell J
Q, Vaisse C, Foster K E, Frayo R S, Schwartz M W, Basdevant A,
Weigle D S. Elevated plasma ghrelin levels in Prader Willi
syndrome. Nat Med 8(7):643-644 (2002). [0190] 11. Haqq A M F,
Farooqi I S, O'Rahilly S, Stadler D D, Rosenfeld R G, Pratt K L,
Lafranchi S H, Purnell J Q. Serum ghrelin levels are inversely
correlated with body mass index, age, and insulin concentrations in
normal children and are markedly increased in Prader-Willi
syndrome. J Clin Endocrinol Metab 88(1):174-178 (2003). [0191] 12.
Mifune H, Nishi Y, Tajiri Y, Masuyama T, Hosoda H, Kangawa K,
Kojima M. Increased production of active ghrelin is relevant to
hyperphagia in nonobese spontaneously diabetic Torii rats.
Metabolism. 2011 Oct. 14. [Epub ahead of print] [0192] 13. Misra M,
Miller K K, Kuo K, Griffin K, Stewart V, Hunter E, Herzog D B,
Klibanski A. Secretory dynamics of ghrelin in adolescent girls with
anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol
Metab 289(2):E347-E356 (2005). [0193] 14. Nikolopoulos D,
Theocharis S, Kouraklis G. Ghrelin: a potential therapeutic target
for cancer. Regul Pept 163(1-3):7-17 (2010). [0194] 15. van der
Lely A J, Tschop M, Heiman M L, Ghigo E; Biological, physiological,
pathophysiological, and pharmacological aspects of ghrelin. Endocr
Rev 25:426-457 (2004). [0195] 16. Asakawa A, lnui A, Fujimiya M,
Sakamaki R, Shinfuku N, Ueta Y, Meguid M M, Kasuga M. Stomach
regulates energy balance via acylated ghrelin and desacyl ghrelin.
Gut. January; 54(1):18-24 (2005). [0196] 17. Zhang W, Chai B, Li J
Y, Wang H, Mulholland M W. Effect of des-acyl ghrelin on adiposity
and glucose metabolism. Endocrinology. September; 149(9):4710-6.
(2008) [0197] 18. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli
G, Papotti M, Abribat T, Van Der Lely A J, Ghigo E. Non-acylated
ghrelin counteracts the metabolic but not the neuroendocrine
response to acylated ghrelin in humans. J Clin Endocrinol Metab.
June; 89(6):3062-5 (2004). [0198] 19. Gauna C, Meyler F M, Janssen
J A, Delhanty P J, Abribat T, van Koetsveld P, Hofland L J, Broglio
F, Ghigo E, van der Lely A J. Administration of acylated ghrelin
reduces insulin sensitivity, whereas the combination of acylated
plus unacylated ghrelin strongly improves insulin sensitivity. J
Clin Endocrinol Metab. October; 89(10):5035-42 (2004). [0199] 20.
St-Pierre D H, Karelis A D, Coderre L, Malita F, Fontaine J,
Mignault D, Brochu M, Bastard J P, Cianflone K, Doucet E, Imbeault
P, Rabasa-Lhoret R. Association of acylated and nonacylated ghrelin
with insulin sensitivity in overweight and obese postmenopausal
women. J Clin Endocrinol Metab. January; 92(1):264-9 (2007). [0200]
21. Pacifico L, Poggiogalle E, Costantino F, Anania C, Ferraro F,
Chiarelli F, Chiesa. Acylated and nonacylated ghrelin levels and
their associations with insulin resistance in obese and normal
weight children with metabolic syndrome. Eur J Endocrinol.
December; 161(6):861-70 (2009). [0201] 22. Barazzoni R, Zanetti M,
Ferreira C, Vinci P, Pirulli A, Mucci M, Dore F, Fonda M, Ciocchi
B, Cattin L, Guarnieri G. Relationships between desacylated and
acylated ghrelin and insulin sensitivity in the metabolic syndrome.
J Clin Endocrinol Metab. October; 92(10):3935-40 (2007). [0202] 23.
Rodriguez A, Gomez-Ambrosi J, Catalan V, Gil M J, Becerril S, Sainz
N, Silva C, Salvador J, Colina I, Fruhbeck G. Acylated and desacyl
ghrelin stimulate lipid accumulation in human visceral adipocytes.
Int J Obes (Lond). May; 33(5):541-52 (2009). [0203] 24. Schellekens
H, Dinan T G, Cryan J F. Lean mean fat reducing "ghrelin" machine:
Hypothalamic ghrelin and ghrelin receptors as therapeutic targets
in obesity. Neuropharmacology 58(1):2-19 (2010). [0204] 25.
Gualillo O, Lago F, Dieguez C. Introducing GOAT: a target for
obesity and anti-diabetic drugs? Trends Pharmacol Sci 29(8):398-401
(2008). [0205] 26. Hillman J B, Tong J, Tschop M. Ghrelin biology
and its role in weight-related disorders. Discov Med. June;
11(61):521-8 (2011). [0206] 27. Kumar R, Salehi A, Rehfeld J F,
Hoglund P, Lindstrom E, Hakanson R. Proghrelin peptides: Desacyl
ghrelin is a powerful inhibitor of acylated ghrelin, likely to
impair physiological effects of acyl ghrelin but not of obestatin A
study of pancreatic polypeptide secretion from mouse islets. Regul
Pept. September 24; 164(2-3):65-70 (2010) [0207] 28. Cummings D E,
Weigle D S, Frayo R S, Breen P A, Ma M K, Dellinger E P, Purnell J
Q. Plasma ghrelin levels after diet-induced weight loss or gastric
bypass surgery. N Engl J Med. May 23; 346(21):1623-30 (2002).
[0208] 29. Sumithran P, Prendergast L A, Delbridge E, Purcell K,
Shulkes A, Kriketos A, Proietto J. Long-term persistence of
hormonal adaptations to weight loss. N Engl J Med. October 27;
365(17):1597-604 (2011). [0209] 30. Kiewiet R M, van Aken M O, van
der Weerd K, Uitterlinden P, Themmen A P, Hofland L J, de Rijke Y
B, Delhanty P J, Ghigo E, Abribat T, van der Lely A J. Effects of
acute administratio of acylated and unacylated ghrelin on glucose
and insulin concentratios in morbidly obese subjects without overt
diabetes. Eur J Endocrinol 161:567-573 (2009). [0210] 31. Gauna C,
Delhanty P J D, Hofland L J, Janssen J, Broglio F, Ross R J M,
Ghigo E, van der Lely A J. Ghrelin stimulates, whereas des-octanoyl
ghrelin inhibits, glucose output by primary hepatocytes. Journal of
Clinical Endocrinology and Metabolism 90:1055-1060 (2005). [0211]
32. Gauna C, Kiewiet R M, Janssen J A, van de Zande B, Delhanty P
J, Ghigo E, Hofland L J, Themmen A P, van der Lely A J. Unacylated
ghrelin acts as a potent insulin secretagogue in glucose-stimulated
conditions. Am J Physiol Endocrinol Metab 293:E697-704 (2007).
[0212] 33. Granata R, Settanni F, Gallo D, Trovato L, Biancone L,
Cantaluppi V, Nano R, Annunziata M, Campiglia P, Arnoletti E, Ghe
C, Volante M, Papotti M, Muccioli G, Ghigo E. Obestatin promotes
survival of pancreatic beta-cells and human islets and induces
expression of genes involved in the regulation of beta-cell mass
and function. Diabetes 57:967-979 (2008). [0213] 34. Longo K A,
Charoenthongtrakul S, Giuliana D J, Govek E K, McDonagh T, Qi Y,
DiStefano P S, Geddes B J. Improved insulin sensitivity and
metabolic flexibility in ghrelin receptor knockout mice. Regul Pept
150:55-61 (2008). [0214] 35. Nonogaki K, Nozue K, Oka Y.
Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B
receptor genes and plasma des-acyl ghrelin levels in Ay mice.
Endocrinology 147:5893-5900 (2006). [0215] 36. Kitamura S, Yokota
I, Hosoda H, Kotani Y, Matsuda J, Naito E, Ito M, Kangawa K, Kuroda
Y. Ghrelin concentration in cord and neonatal blood: relation to
fetal growth and energy balance. J Clin Endocrinol Metab. 2003
November; 88(11):5473-7.
Sequence CWU 1
1
30128PRTHomo sapiens 1Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg
Val Gln Gln Arg Lys 1 5 10 15 Glu Ser Lys Lys Pro Pro Ala Lys Leu
Gln Pro Arg 20 25 214PRTHomo sapiens 2Gly Ser Ser Phe Leu Ser Pro
Glu His Gln Arg Val Gln Gln 1 5 10 318PRTHomo sapiens 3Gly Ser Ser
Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys 1 5 10 15 Glu
Ser 45PRTHomo sapiens 4Gly Ser Ser Phe Leu 1 5 512PRTHomo sapiens
5Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg 1 5 10 68PRTHomo
sapiens 6Ser Pro Glu His Gln Arg Val Gln 1 5 76PRTHomo sapiens 7Glu
His Gln Arg Val Gln 1 5 85PRTHomo sapiens 8Glu His Gln Arg Val 1 5
913PRTHomo sapiens 9Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu
Ser 1 5 10104PRTHomo sapiens 10Glu His Gln Arg 1 114PRTHomo sapiens
11His Gln Arg Val 1 128PRTHomo sapiens 12Ser Pro Asp His Gln Arg
Val Gln 1 5 138PRTHomo sapiens 13Ser Pro Glu His Gln Lys Val Gln 1
5 148PRTHomo sapiens 14Gly Pro Glu His Gln Arg Val Gln 1 5
158PRTHomo sapiens 15Ala Pro Glu His Gln Arg Val Gln 1 5 168PRTHomo
sapiens 16Ser Ala Glu His Gln Arg Val Gln 1 5 178PRTHomo sapiens
17Ser Pro Ala His Gln Arg Val Gln 1 5 188PRTHomo sapiens 18Ser Pro
Glu Ala Gln Arg Val Gln 1 5 198PRTHomo sapiens 19Ser Pro Glu His
Ala Arg Val Gln 1 5 208PRTHomo sapiens 20Ser Pro Glu His Gln Ala
Val Gln 1 5 218PRTHomo sapiens 21Ser Pro Glu His Gln Arg Ala Gln 1
5 228PRTHomo sapiens 22Ser Pro Glu His Gln Arg Val Ala 1 5
238PRTHomo sapiensMOD_RES(1)..(1)ACETYLATION 23Ser Pro Glu His Gln
Arg Val Gln1 5248PRTHomo sapiensMOD_RES(1)..(1)ACETYLATION 24Ser
Pro Glu His Gln Arg Val Gln1 5258PRTHomo
sapiensMISC_FEATURE(1)..(8)Cyclic 25Ser Pro Glu His Gln Arg Val
Gln1 5268PRTHomo sapiensMISC_FEATURE(3)..(6)Cyclic 26Ser Pro Glu
His Gln Lys Val Gln1 5278PRTHomo sapiensMOD_RES(1)..(1)ACETYLATION
27Ser Pro Glu His Gln Lys Val Gln1 5288PRTHomo
sapiensMOD_RES(1)..(1)ACETYLATION 28Ser Pro Glu His Gln Lys Val
Gln1 5293PRTHomo sapiens 29His Gln Arg 1 3014PRTHomo sapiens 30Gln
Gln Val Arg Gln His Glu Pro Ser Leu Phe Ser Ser Gly 1 5 10
* * * * *